Pfizer (PFE) Income from Continuing Operations (2009 - 2026)
Pfizer (PFE) posted quarterly Income from Continuing Operations of 2709000000.0 for Q1 2026, down 8.91% year-over-year from 2974000000.0 in Q1 2025, and up 265.18% quarter-over-quarter from 1640000000.0 in Q4 2025.
Pfizer (PFE) Income from Continuing Operations (2009 - 2026) Analysis & Trends
Pfizer (PFE) has reported Income from Continuing Operations for 18 consecutive years, with 2709000000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 8.91% year-over-year to 2709000000.0; the TTM figure through Mar 2026 stood at 7522000000.0 (down 45.39% YoY), while the FY2025 annual figure was 7786000000.0, down 3.29% from the prior year.
- Income from Continuing Operations rose to 2709000000.0 in Q1 2026 per PFE's latest filing, from 1640000000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 9877000000.0 in Q3 2022 and bottomed at 3349000000.0 in Q4 2023.
- Historically, Income from Continuing Operations has averaged 3353538461.54 across 5 years, with a median of 2974000000.0 in 2025.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations plunged 98.68% — and 2025, when it soared 9264.52%.
- Pfizer's Income from Continuing Operations stood at 9877000000.0 in 2022, then slumped by 133.91% to 3349000000.0 in 2023, then jumped by 328.13% to 7640000000.0 in 2024, then plunged by 121.47% to 1640000000.0 in 2025, then soared by 265.18% to 2709000000.0 in 2026.
- Business Quant data shows PFE's Income from Continuing Operations at 2709000000.0 in Q1 2026, 1640000000.0 in Q4 2025, and 3550000000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 3.26 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 2.51 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -246.00 Mn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 207.96 Mn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 17.71 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | -246.00 Mn |
| Mar 29, 2026 | 2.71 Bn |
| Dec 31, 2025 | -1.64 Bn |
| Sep 28, 2025 | 3.55 Bn |
| Jun 29, 2025 | 2.90 Bn |
| Mar 30, 2025 | 2.97 Bn |
| Sep 29, 2024 | 7.64 Bn |
| Jun 30, 2024 | 31.00 Mn |
| Mar 31, 2024 | 3.13 Bn |
| Dec 31, 2023 | -3.35 Bn |
| Jul 2, 2023 | 2.34 Bn |
| Apr 2, 2023 | 5.56 Bn |
| Jul 3, 2022 | 9.88 Bn |
| Apr 3, 2022 | 7.88 Bn |
| Oct 3, 2021 | 18.88 Bn |
| Jul 4, 2021 | 5.83 Bn |
| Apr 4, 2021 | 4.88 Bn |
| Sep 27, 2020 | 6.00 Bn |
| Jun 28, 2020 | 2.60 Bn |
| Mar 29, 2020 | 2.48 Bn |